Arcede Pharma is focused on developing innovative drug candidates aimed at treating chronic respiratory diseases, specifically chronic obstructive pulmonary disease (COPD) and severe asthma. The company emphasizes its commitment to creating patent-protected substances that utilize new modes of action, which have shown promising results in preclinical studies. Their lead drug candidate, RCD405, is currently in the preclinical phase and is part of the RESP9000 project, indicating a structured approach to research and development in this therapeutic area.

The company's strategy involves forming collaborations with academic research groups, biotech firms, and global pharmaceutical companies to leverage expertise throughout the drug development process. By partnering with strategic entities that can assume financial and operational responsibilities, Arcede Pharma aims to enhance the efficiency of bringing their innovative treatments to market. Their vision is centered on improving the quality of life for patients suffering from chronic respiratory conditions through the development of effective and novel therapeutic options.

Sweden

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients.

Arcede Pharma

Company Details